SCH-530348
From Wikipedia, the free encyclopedia
 |
|
|
SCH-530348
|
|
| Systematic (IUPAC) name | |
| Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C29H33FN2O4 |
| Mol. mass | 492.58 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
SCH-530348 is a thrombin receptor (PAR-1) antagonists based on the natural product himbacine. Developed by Schering-Plough, SCH-530348 is a potential treatment for acute coronary syndrome chest pain caused by coronary artery disease.[1]
[edit] References
- ^ Samuel Chackalamannil (2008). "Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity". Journal of Medicinal Chemistry. doi:.
